Navigation Links
Entest Biomedical Enters into Discussions with Laser Manufacturer to Develop Proprietary Photoceutical Device for COPD Treatment

Laser-type device to be coupled with Stem Cell Therapy.

San Diego, CA (PRWEB) November 24, 2009 -- Entest Biomedical, Inc. (OTCBB: ENTB) announced that it has initiated discussions with a manufacturer of lasers regarding the development of a proprietary laser device which shall be owned by Entest and used in conjunction with several stem cell therapies currently being developed by Entest. These therapies are aimed at increasing efficacy in treating Chronic Obstructive Pulmonary Disease (COPD). A spokesman for Entest stated that this particular manufacturer was approached due to their success in commercializing medical devices in the North American market.

“Biotechnology R&D companies like Entest frequently have intellectual property tied to medical devices under development. Entest’s planned usage of laser-type devices in treating COPD requires the adaptation of current laser technology into a device that supports the Company’s Stem Cell / Photoceutical therapy.” said David Koos, Chairman and CEO of Entest. “Companies such as PhotoThera in Carlsbad, California, have successfully used this approach in developing their laser-based NeurotheraÒ technology for treating ischemic stroke patients (currently in Phase III clinical trials).”

Entest’s patent-pending approach revolves around the use of the patient’s own stem cells in combination with specific laser wavelengths to repair damaged lung tissue of patients with COPD.

Ernest’s goal is the generation of schematics, code, and intellectual property pertaining to the new device which will serve as the basis for regulatory filings and FDA development of the Entest “regenerative photoceutical” approach to COPD.

About Entest BioMedical Inc.:

Entest BioMedical Inc. (OTCBB: ENTB) is a majority owned subsidiary of Bio-Matrix Scientific Group Inc (OTCBB: BMSN). The Company is involved with the development of stem cell therapy treatments for Chronic Obstructive Pulmonary Disease (COPD), immuno-cancer therapies, testing procedures for diabetes, stem cell research applications for diabetes and other illnesses. The Company also is involved with medical device development (including stem cell extraction instrumentation).


This news release may contain forward-looking statements. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements. The risks and uncertainties to which forward-looking statements are subject include, but are not limited to, the effect of government regulation, competition and other material risks.


David R. Koos, Chairman & CEO
619.702.1404 Direct
619.330.2328 Fax

Entest BioMedical Inc.


Read the full story at

Source: PRWeb
Copyright©2009 Vocus, Inc.
All rights reserved

Related medicine news :

1. Entest BioMedical Files 3rd Patent Application for COPD Stem Cell Treatment
2. Entest BioMedical, Inc. Discusses How Therapies in Development May Yield Lucrative Revenue Streams for the Company
3. Entest BioMedical Inc. Adds Former National Cancer Institute Researcher to Scientific Advisory Board With Focus on Stem Cell Cancer Patient Therapies
4. Bio-Matrix Scientific Group and Entest BioMedical Sign Contract With UCLA Researcher to Develop Gestational Diabetes Screening Test
5. Largest British Fund for Biomedical Research Finances Project on Breakbone Fever in Leuven (K.U.Leuven)
6. Biomedical Research Centre searches for immunological biomarkers
7. Nine International Research Teams Collaborate to Successfully Operate Multiple Biomedical Robots from Numerous Locations
8. Sponsor-A-Scientist: New Option to Fund Biomedical Research
9. Biomedical Research Centre developing enhanced cells as therapies
10. Environmental Tectonics Corporations BioMedical Systems Division Announces First BARA-MED(R) Monoplace Hyperbaric Chamber Sale in Romania
11. New test for safer biomedical research results
Post Your Comments:
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... On Friday, ... presented a Bronze Wellness at Work award to iHire in recognition of their exemplary ... part of the 7th annual Maryland Workplace Health & Wellness Symposium at the BWI ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... June 19, ... the dangers associated with chronic pain and the benefits of holistic treatments, Serenity ... who are suffering with Sickle Cell Disease. , Sickle Cell Disease (SCD) is a ...
(Date:6/24/2016)... , ... June 24, 2016 , ... ... offering micro-osteoperforation for accelerated orthodontic treatment. Dr. Cheng has extensive experience with all ... brackets , AcceleDent, and accelerated osteogenic orthodontics. , Micro-osteoperforation is a revolutionary ...
(Date:6/24/2016)... ... June 24, 2016 , ... EB Medicine ... Making in Emergency Medicine conference in Ponte Vedra Beach, FL. The awards honor ... Emergency Medicine Practice and Pediatric Emergency Medicine Practice. , “With this ...
(Date:6/24/2016)... ... June 24, 2016 , ... National recruitment firm Slone Partners ... with extensive sequencing and genomics experience, as Vice President of North American Capital Sales ... be responsible for leading the sales team in the commercialization of the HTG EdgeSeq ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... 24, 2016   Bay Area Lyme Foundation ... Dean Center for Tick Borne Illness , Harvard ... MIT Hacking Medicine, University of California, Berkeley, and ... the five finalists of Lyme Innovation , ... than 100 scientists, clinicians, researchers, entrepreneurs, and investors ...
(Date:6/24/2016)... June 24, 2016 Dehaier Medical Systems Ltd. ... which develops, markets and sells medical devices and wearable ... signed a strategic cooperation agreement with Hongyuan Supply Chain ... Chain") on June 20, 2016, to develop Dehaier,s new ... cooperation agreement, Dehaier will leverage Hongyuan Supply Chain,s sales ...
(Date:6/24/2016)... , June 24, 2016   Pulmatrix, Inc ., ... developing innovative inhaled drugs, announced today that it was ... Investments reconstituted its comprehensive set of U.S. and ... "This is an important milestone for Pulmatrix," said Chief ... shareholder awareness of our progress in developing drugs for ...
Breaking Medicine Technology: